Lara S van der Schoot

7PUBLICATIONS
6CO-AUTHORS
Clinical pharmacology and therapeuticsBioinformatic methods developmentGene and molecular therapyToxicology (incl. clinical toxicology)Cell development, proliferation and death
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 03, 2023
Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice.

L S van der Schoot, J J Janssen, M T Bastiaens

|Dec 06, 2022
National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure.

L S van der Schoot, E M Baerveldt, W A van Enst

|Oct 17, 2021
Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.

Lara S van der Schoot, Juul M P A van den Reek, Lynda Grine

|Sep 01, 2021
Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide.

M E van Muijen, L S van der Schoot, J M P A van den Reek

|Jun 10, 2019
Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry.

L S van der Schoot, J M P A van den Reek, J M M Groenewoud

Pageof 2

Frequent Collaborators

3 joint publications

Juul M P A van den Reek

2 joint publications

Elke M G J de Jong

1 joint publications

M M B Seyger

1 joint publications

Selma Atalay